C
CLAS
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, CLAS has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +37% growth.
Stocks Performance
CLAS vs S&P TSX Composite Index (Canada)
Performance Gap
CLAS vs S&P TSX Composite Index (Canada)
Performance By Year
CLAS vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Claritas Pharmaceuticals Inc
Glance View
Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in Novato, California. The company went IPO on 2005-05-19. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
